Companies To Watch

  1. Companies To Watch: Acceleron 8/2/2018

    Acceleron has four drugs in development in the hematology, neuromuscular, and pulmonary disease areas. Its lead drug luspatercept has completed Phase 3 trials for treating myelodysplastic syndromes (MDS).

  2. Companies To Watch: Sensorion 6/1/2018

    This French company is addressing vertigo and hearing loss inside the inner ear.

  3. Companies To Watch: Landos Biopharma 5/2/2018

    Our company to watch this month is Landos Biopharma, which is aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.

  4. Companies To Watch: CytoDyn 4/6/2018

    CytoDyn’s expressed ambitions seem bold but reasonably free of hyperbole. It is only natural to hope for the best possible outcome here, considering the obvious need for new HIV and other immunological therapies.

  5. Companies To Watch Roundup 2017 3/7/2018

    We check in with the companies we profiled from this section in 2017 to see what has changed … if anything.

  6. Companies To Watch: AmpliPhi Biosciences 3/7/2018

    AmpliPhi Biosciences is pushing bacteriophage-therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.

  7. Companies To Watch: Zavante 2/7/2018

    This month’s Company To Watch is 10-person Zavante, which is challenging drug resistance with a retooled antibiotic and a broad mechanism of action.

  8. Companies To Watch: Daré Bioscience 1/9/2018

    Bridging to commercialization of women’s reproductive health products — starting with a novel contraceptive.

  9. Companies To Watch: Abivax 11/8/2017

    With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection.  It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).

  10. Companies To Watch: Madrigal Pharmaceuticals 10/10/2017

    Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.